

Poster Sessions at the San Antonio Breast Cancer Symposium

The posters listed here feature Dana-Farber faculty and staff as either first author and presenter, senior author, or both.

All times listed are Central Standard Time. Times and locations subject to change by SABCS

Poster Session 1: Wednesday, December 6 | 12 – 2 p.m. CST

Poster	Dana-Farber Presenter and/or Author
PO1-01-01: ECOG-ACRIN EA1211: Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT Trial)	Presenter: Heather Jacene, MD
PO1-03-08: Association of patient-reported triple-negative breast cancer (TNBC) knowledge with clinical trial participation	Presenter: Megan Tesch, MD Senior author: Ana Garrido-Castro, MD
PO1-05-12: Pooled clinical trial data analyses comparing the biology of HER2-low vs HER2-0 breast cancer in patients with metastatic breast cancer following treatment with standard single agent chemotherapy	Senior author: Sara Tolaney, MD, MPH
PO1-08-04: Universal Germline Genetic Testing for Breast Cancer: Implementation in a Rural Practice and Impact on Shared Decision Making	Senior author: Hannah Montgomery
PO1-09-10: County-level Social Vulnerability and Survival among Women with Inflammatory Breast Cancer	Senior author: Filipa Lynce, MD
PO1-14-10: Comprehensive clinicogenomic characterization of inflammatory breast cancer	Presenter: Nolan Priedigkeit, MD, MPH Senior author: Nancy Lin, MD
PO1-18-04: Neoadjuvant pembrolizumab + decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-breast cancer (NCT02957968)	Senior author: Tasnim Rahman

Poster Session 2: Wednesday, December 6 | 5 – 7 p.m. CST

Poster	Dana-Farber Presenter and/or Author
PO2-01-09: Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study	Presenter: Erica Mayer, MD, MPH
PO2-02-14: Development of a multi-institutional, photograph-rich clinical dataset to test and validate a novel inflammatory breast cancer (IBC) scoring system	Presenter: Filipa Lynce, MD
PO2-03-06: Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC)	Presenter: Filipa Lynce, MD
PO2-04-01: Predictors of exceptional response to first line HER2-targeted therapy for metastatic breast cancer	Presenter: Stefania Morganti, MD Senior author: Heather Parsons, MD, MPH
PO2-10-07: Patterns of presentation, treatment and survival for older patients with metastatic breast cancer (MBC): results from a large prospective registry	Presenter: Melissa Hughes Senior author: Rachel Freedman, MD, MPH
PO2-10-08: Contemporary HER2-Positive MBC Treatment Recommendations Among Community Healthcare Professionals: Analysis of an Online Interactive Decision Support Tool	Senior author: Sara Tolaney, MD, MPH
PO2-11-02: Incidence, treatment patterns and outcomes of breast cancer during the first year of the COVID pandemic: A population-based study	Presenter: Jose Pablo Leone, MD Senior author: Nancy Lin, MD
PO2-16-02: RBsig gene-expression signature in patients with endocrine resistant metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial	Senior author: Meredith Regan, ScD
PO2-20-01: The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+ Metastatic Breast Cancer (TBCRC 062)	Presenter: Heather Parsons, MD, MPH Senior author: Nancy Lin, MD
PO2-20-09 Hiding in plain sight: A heterogeneous response in a patient with metastatic HR+/HER2- breast cancer	Presenter: Nolan Priedigkeit, MD, PhD Senior author: Heather Parsons, MD, MPH
PO2-20-10: Exceptional long-term disease control on pembrolizumab monotherapy in a patient with TMB-high PMS2-mutated MMR-deficient triple negative breast cancer brain metastasis	Senior author: Nancy Lin, MD

Poster Session 2 continued >

PO2-27-12: Genomic determinants of benefit to nivolumab (NIVO) plus low dose ipilimumab (IPI) among patients (pts) with hypermutated HER2-negative metastatic breast cancer (MBC): results of NIMBUS trial	Senior author: Elizabeth Mittendorf, MD, PhD
--	--

Poster Session 3: Thursday, December 7 | Noon – 2 p.m. CST

Poster	Dana-Farber Presenter and/or Author
PO3-01-09: Results of a prospective observational study evaluating the impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR+/HER2- breast cancer	Senior author: Elizabeth Mittendorf, MD, PhD
PO3-02-05: Racial and Ethnic Differences in Clinical Outcomes among North American Patients with Hormone Receptor-Positive, HER2-negative, Early Breast Cancer in the PALLAS Trial (AFT-05)	Presenter: Olga Kantor, MD Senior author: Erica Mayer, MD, MPH
PO3-03-05: Clinical outcomes in early-stage TNBC according to HER2-low status	Presenter: Ana Garrido-Castro, MD
PO3-08-08: Basal-Luminal (BL) Cells in Histologically Normal and Malignant Breast Tissue from BRCA1 and BRCA2 Carriers	Senior author: Deborah Dillon, MD
PO3-11-10: Second primary non-breast cancers in young breast cancer survivors	Senior author: Ann Partridge, MD, MPH
PO3-12-05: Patient (pt)-provider communication challenges about side effects/toxicities from metastatic breast cancer (mBC) treatments	Presenter: Sarah Sammons, MD
PO3-13-07: MUC1-C integrates chronic activation of interferon pathways with chromatin remodeling in treatment resistance of triple-negative breast cancer	Senior author: Donald Kufe, MD
PO3-14-02: Clinical and genomic factors predictive of outcomes in first line treatment of hormone receptor-positive metastatic breast cancer	Presenter: Albert Grinshpun, MD, MSc Senior author: Nancy Lin, MD
PO3-14-03: Ultra-sensitive detection of circulating tumor DNA in patients undergoing neoadjuvant endocrine therapy for hormone receptor-positive early breast cancer	Presenter: Albert Grinshpun, MD, MSc Senior author: Nancy Lin, MD
PO3-20-06 TRUDI: A phase II study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for stage III HER2-expressing Inflammatory breast cancer	Presenter: Paolo Tarantino, MD

Poster Session 4: Thursday, December 7 | 5 – 7 p.m. CST

Poster	Dana-Farber Presenter and/or Author
PO4-01-11: Ovarian function suppression (OFS) use beyond five years?: Young breast cancer patient preferences	Presenter: Kate Dibble, PhD Senior author: Ann Partridge, MD, MPH
PO4-06-02: Frequency of presentation and outcomes of stage IV breast cancer over the past decade: a population-based study	Senior author: Nancy Lin, MD
PO4-06-07: Efficacy and safety of futibatinib in patients with locally advanced/metastatic triple-negative breast cancer harboring FGFR2 gene amplification: final results from the phase 2, open-label FOENIX-MBC2 study	Presenter: Antonio Giordano, MD, PhD
PO4-08-05: Disparities in Genetic Testing Patterns and Positivity Among Patients with Breast Cancer in the CancerLINQ Real-World Oncology Database	Presenter: Olga Kantor, MD Senior author: Elizabeth Mittendorf, MD, PhD
PO4-09-09: Deep Immunoprofiling Demonstrates Racial Differences in the Peripheral Immune System in Women at Risk for Breast Cancer	Presenter: Esther Ogayo Senior author: Elizabeth Mittendorf, MD, PhD
PO4-12-11: Patient (pt) time burden with IV vs subcutaneous (SC) administration of trastuzumab/pertuzumab (HP): A time and motion (T+M) substudy of a single arm phase II trial of adjuvant endocrine therapy plus HP for stage I HER2+ breast cancer	Presenter: Adrienne Waks, MD
PO4-16-01: EZH2 is Overexpressed in Invasive Carcinoma and DCIS in both BRCA1 and BRCA2 Mutation Carriers	Senior author: Deborah Dillon, MD
PO4-16-09: Enhancing Research on Inflammatory Breast Cancer through Count Me In: Assessing the Accuracy of Self-Reported Diagnoses	Presenter: Elizabeth Troll Senior author: Filipa Lynce, MD
PO4-18-10: Randomized controlled trial of Young, Empowered & Strong (YES), a web-based patient-reported symptom monitoring and self-management portal for adolescent and young adult (AYA) breast cancer (BC) survivors	Senior author: Ann Partridge, MD, MPH
PO4-19-05: OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy (Alliance A012103)	Presenter: Sara Tolaney, MD, MPH
PO4-23-08: Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer	Presenter: Nicole Traphagen, PhD

Poster Session 5: Friday, December 8 | Noon – 2 p.m. CST

Poster	Dana-Farber Presenter and/or Author
PO5-05-14: Survival in Young Women with De Novo or Recurrent Metastatic Breast Cancer	Presenter: Leticia Varella, MD
PO5-10-03: A Translational Epidemiologic Approach to Understand Disparities in Triple Negative Breast Cancer: Integrating Germline Genomics, Genetic Ancestry, and Neighborhood Disadvantage	Senior author: Timothy Rebbeck, PhD
PO5-12-06: Minimization of treatment toxicity/side effects and their impact on quality of life (QoL) in patients (pts) with ER+/HER2-metastatic breast cancer (mBC)	Presenter: Sarah Sammons, MD
PO5-20-02: Secondary BRain metastases prevention after Isolated intracranial progression on trastuzumab/pertuzumab or T-DM1 in pts with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with addition of Tucatinib (BRIDGET)	Presenter: Sarah Sammons, MD
PO5-22-10: Are contralateral prophylactic mastectomy rates impacted by ASBrS guidelines to offer germline genetic testing to all patients with breast cancer? Results from a large, prospective, single-institution cohort	Senior author: Tari King, MD